HILDEN, Germany and GERMANTOWN, Maryland, May 31, 2016 /PRNewswire/ --
QIAGEN N.V. (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) today announced that an extensive package consisting of a quality control set and verification data will be offered with its GeneReader NGS System, reinforcing the proven accuracy of its next-generation sequencing (NGS) workflow and facilitating system setup, quality assurance and training for laboratories. QIAGEN has incorporated the Horizon Discovery Group's industry-standard reference control data set into the GeneReader NGS workflow to support clinical cancer research users from Sample to Insight.
In addition, QIAGEN's GeneRead QIAact Actionable Insights Tumor Panel, the first in a family of multiplex panels for the GeneReader NGS System, has demonstrated the highest levels of accuracy, consistency and reliability in extensive testing compared with Horizon's control data. The workflow achieved full concordance with the Horizon Quantitative Multiplex FFPE Reference Standards in correctly identifying eight critical cancer-linked variants above 5% allelic frequency covered by the control data. The QIAact panel targets 12 clinically actionable genes often analyzed in the most prevalent types of cancer research, including breast, ovarian, colorectal, lung and melanoma.
Click here for full press release.
SOURCE QIAGEN N.V.